Somatropin (rHGH)

Research Profile

Somatropin is a 191-amino acid recombinant human growth hormone (rHGH) produced via recombinant DNA technology, identical in sequence and biological activity to endogenous pituitary growth hormone. It exerts its effects by binding to growth hormone receptors in multiple tissues, triggering downstream signaling cascades including the JAK2/STAT5 pathway, which drives hepatic production of Insulin-like Growth Factor 1 (IGF-1). Through IGF-1 and direct receptor activation, somatropin promotes protein synthesis, skeletal muscle hypertrophy, bone mineralization, and lipolysis — the breakdown of adipose tissue for energy. In research settings, somatropin is studied extensively for its role in growth hormone deficiency models, body composition regulation, tissue repair, metabolic disorders, and aging-related decline in anabolic signaling. Its structural identity to native GH gives it a well-characterized receptor binding profile and predictable pharmacodynamics compared to synthetic GH analogues.